Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Waldenstrom's Macroglobulinemia Recurrent”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Testing effectiveness (Phase 2)Ended earlyNCT00265928
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Virginia 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07791498
What this trial is testing

Teclistamab In Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Massachusetts General Hospital 24
Testing effectiveness (Phase 2)WithdrawnNCT00003512
What this trial is testing

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom Macroglobulinemia
Burzynski Research Institute
Early research (Phase 1)Looking for participantsNCT06980116
What this trial is testing

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell MalignanciesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 85
Testing effectiveness (Phase 2)Study completedNCT00004107
What this trial is testing

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia

Who this might be right for
LeukemiaLymphoma
Garden State Cancer Center at the Center for Molecular Medicine and Immunology 18
Testing effectiveness (Phase 2)Study completedNCT02332980
What this trial is testing

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue+20 more
Mayo Clinic 65
Testing effectiveness (Phase 2)Study completedNCT00936611
What this trial is testing

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 39
Not applicableEnded earlyNCT05645744
What this trial is testing

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Lymphocytic Leukemia in RelapseSmall Lymphocytic Lymphoma, Relapsed+8 more
Mustang Bio 3
Testing effectiveness (Phase 2)Ended earlyNCT03506373
What this trial is testing

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Who this might be right for
Recurrent Waldenstrom MacroglobulinemiaRefractory Waldenstrom MacroglobulinemiaWaldenstrom Macroglobulinemia
Mayo Clinic 21
Early research (Phase 1)Ended earlyNCT01198067
What this trial is testing

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Who this might be right for
Recurrent Waldenstrom MacroglobulinemiaRefractory Waldenstrom Macroglobulinemia
M.D. Anderson Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT01614821
What this trial is testing

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute 63
Testing effectiveness (Phase 2)Study completedNCT01647971
What this trial is testing

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkins LymphomaB-cell LymphomaWaldenstrom's Macroglobulinemia+4 more
TG Therapeutics, Inc. 39
Large-scale testing (Phase 3)Not Yet RecruitingNCT07766421
What this trial is testing

Evaluation of Iopofosine I 131 vs. R-CD in WM Patients

Who this might be right for
Waldenstrom MacroglobulinaemiaWaldenstrom MacroglobulinemiaWaldenstrom's Macroglobulinaemia Refractory+2 more
Cellectar Biosciences, Inc. 219
Testing effectiveness (Phase 2)Study completedNCT03015896
What this trial is testing

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Who this might be right for
Grade 3a Follicular LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell Lymphoma+12 more
David Bond, MD 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT03147885
What this trial is testing

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Extranodal Marginal Zone Lymphoma+12 more
Barbara Ann Karmanos Cancer Institute 43
Testing effectiveness (Phase 2)Ended earlyNCT03269552
What this trial is testing

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Who this might be right for
Marginal Zone LymphomaRecurrent Marginal Zone LymphomaRecurrent Waldenstrom Macroglobulinemia+3 more
University of Washington 4
Testing effectiveness (Phase 2)Study completedNCT04440059
What this trial is testing

ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia Refractory
Beijing InnoCare Pharma Tech Co., Ltd. 47
Testing effectiveness (Phase 2)Ended earlyNCT03246906
What this trial is testing

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAggressive Non-Hodgkin Lymphoma+14 more
Fred Hutchinson Cancer Center 150
Early research (Phase 1)Study completedNCT02950220
What this trial is testing

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+16 more
Kami Maddocks 2
Testing effectiveness (Phase 2)Study completedNCT01381692
What this trial is testing

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Who this might be right for
Recurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma+8 more
National Cancer Institute (NCI) 9
Next Page